Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma

被引：149

作者：

Kawaguchi, Yoshihiko ^{[1
]}

Kono, Koji ^{[1
]}

Mimura, Kousaku ^{[1
]}

Sugai, Hidemitsu ^{[1
]}

Akaike, Hidenori ^{[1
]}

Fujii, Hideki ^{[1
]}

机构：

[1] Univ Yamanashi, Dept Surg 1, Chuo City, Yamanashi 4093898, Japan

来源：

INTERNATIONAL JOURNAL OF CANCER | 2007年 / 120卷 / 04期

关键词：

cetuximab; EGFR; esophageal cancer; ADCC; TGF-beta;

D O I：

10.1002/ijc.22370

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To evaluate the possibility of treatment with antiepidermal growth factor receptor (EGFR) mAb, Cetuximab against esophageal squamous cell carcinoma (SCC), we performed detail analysis of the antibody-dependent cellular cytotoxicity (ADCC) mediated by Cetuximab against esophageal SCC. Esophageal SCC cell lines with various levels of EGFR (n = 8) were evaluated for their Cetuximab-mediated ADCC by Cr-51-release assay. As a result, Cetuximab was able to induce ADCC against EGFR-expressing esophageal SCC and the activities reflected the degree of EGFR expression on the esophageal SCC. The activities of Cetuximab-mediated ADCC by patients' PBMC were impaired in comparison with those by healthy donors' PBMC. Moreover, the inhibition of transforming growth factor (TGF)-beta could enhance Cetuximab-mediated ADCC against TGF-beta-producing SCC. In conclusion, Cetuximab was able to induce ADCC against EGFR-expressing esophageal SCC. Some modalities aiming at enhancing the Cetuximab-mediated ADCC may be necessary for successful Cetuximab treatment of patients with esophageal SCC. (c) 2006 Wiley-Liss. Inc.

引用

页码：781 / 787

页数：7

共 45 条

[1] RADICAL LYMPH-NODE DISSECTION FOR CANCER OF THE THORACIC ESOPHAGUS [J].

AKIYAMA, H ;

TSURUMARU, M ;

UDAGAWA, H ;

KAJIYAMA, Y .

ANNALS OF SURGERY, 1994, 220 (03) :364-373

[2] Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study - JCOG9204 [J].

Ando, N ;

Iizuka, T ;

Ide, H ;

Ishida, K ;

Shinoda, M ;

Nishimaki, T ;

Takiyama, W ;

Watanabe, H ;

Isono, K ;

Aoyama, N ;

Makuuchi, H ;

Tanaka, O ;

Yamana, H ;

Ikeuchi, S ;

Kabuto, T ;

Nagai, K ;

Shimoda, Y ;

Kinjo, Y .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4592-4596

[3] Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years [J].

Ando, N ;

Ozawa, S ;

Kitagawa, Y ;

Shinozawa, Y ;

Kitajima, M .

ANNALS OF SURGERY, 2000, 232 (02) :225-232

[4]

Ciardiello F, 1999, CLIN CANCER RES, V5, P909

[5] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].

Clynes, RA ;

Towers, TL ;

Presta, LG ;

Ravetch, JV .

NATURE MEDICINE, 2000, 6 (04) :443-446

[6]

COHEN S, 1980, J BIOL CHEM, V255, P4834

[7] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[8]

FAN Z, 1994, J BIOL CHEM, V269, P27595

[9] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[10] Suppressed cell-mediated immunity and monocyte and natural killer cell activity following allogeneic immunization of women with spontaneous recurrent abortion [J].

Gafter, U ;

Sredni, B ;

Segal, J ;

Kalechman, Y .

JOURNAL OF CLINICAL IMMUNOLOGY, 1997, 17 (05) :408-419

← 1 2 3 4 5 →